TriangleChimeric Antigen Receptor T-cells (NCT05225363)
Chimeric Antigen Receptor T-cells trial for Platinum-Resistant Ovarian Carcinoma (NCT05225363). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Ovarian cancer is usually found after it has spread across the abdomen. Chemotherapy works, then for many women stops working, and options narrow fast.
The idea: send engineered immune cells to where the cancer actually lives, the lining of the abdomen.
A woman's own T cells are fitted with a receptor for TAG72, a sugar-coated marker most ovarian cancers carry and healthy tissue mostly lacks. After chemotherapy makes room, the cells go not into a vein but through a port into the abdominal cavity, among the tumor deposits. In mice, that regional delivery beat the same cells given by vein.
This trial, at City of Hope with Lorna Rodriguez, asks first whether it is safe. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.